Research programme: small molecule therapeutics - VasGene TherapeuticsAlternative Names: VAS 012
Latest Information Update: 22 Jan 2016
At a glance
- Originator VasGene Therapeutics
- Class Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Jan 2016 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 30 Nov 2010 Preclinical trials in Cancer in USA (unspecified route)